XTNT
Xtant Medical Holdings, Inc.0.7350
+0.0350+5%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
102.90MP/E (TTM)
73.50Basic EPS (TTM)
0.01Dividend Yield
0%Recent Filings
8-K
Note repaid, loan prepaid
Xtant Medical received $10.7 million from Companion Spine on February 27, 2026, fully repaying an $8.2 million note plus interest and settling purchase price adjustments from its December 2025 divestiture of Coflex, CoFix assets, and Paradigm Spine. Total deal value hit $21.4 million. Company applied $2.8 million to prepay its MidCap term loan, leaving $11.1 million outstanding. Cash bolsters balance sheet.
8-K
Note maturity extended to Jan 31
Xtant Medical extended the maturity of its $8.2 million unsecured note from Companion Spine to January 31, 2026, alongside delaying a $1.742 million Paradigm Spine purchase price adjustment to the same date. Both changes amend deals from the December 2025 Coflex/CoFix and Paradigm divestitures, totaling $19.2 million. Streamlines cash inflows. Buyers hold the leverage.
8-K
Divestitures closed, debt cut
Xtant Medical closed its divestiture of Coflex/CoFix assets and Paradigm's OUS hardware business to Companion Spine on December 1, 2025, for $17.5M plus $1.7M cash. Cash payments totaled $11M, with $8.2M as a note due January 15, 2026; $8M repaid term debt, leaving $14.4M outstanding. Divestitures sharpen biologics focus. Pro forma cash grows to $13.4M.
8-K
Stockholders boost equity plan shares
10-Q
Q3 FY2025 results
Xtant Medical swung to $2.5M operating income in Q3 ended September 30, 2025, up from $3.8M loss y/y, on 19% revenue growth to $33.3M driven by $5.5M license revenue and orthobiologics gains (52% of sales), while gross margin hit 66.1% from sales mix. YTD revenue climbed 18% to $101.6M with 65.5% margins, diluted EPS $0.03 on 150M shares. Cash swelled to $10.4M, $7.2M operating cash flow; term debt down to $17.0M (13.2% effective), $5.7M revolver availability. Secured $5.0M non-refundable advances toward pending Q4 sale of Coflex/CoFix assets ($17.5M total) and international hardware ($1.7M). Yet pending asset sale risks disrupting revenue.
ATEC
Alphatec Holdings, Inc.
19.76+0.05
AXGN
AxoGen, Inc.
29.35-0.43
BSX
Boston Scientific Corporation
92.95+0.76
BVS
Bioventus Inc.
7.52+0.02
DYNT
Dynatronics Corp.
0.04+0.00
IART
Integra LifeSciences Holdings C
13.00-0.47
SIBN
SI-BONE, Inc.
19.42+1.01
SNN
Smith & Nephew SNATS, Inc.
32.31+0.08
TNON
Tenon Medical, Inc.
1.10+0.02
ZBH
Zimmer Biomet Holdings, Inc.
90.91-1.52